Holen Sie sich die Stockscreener-App
460.65
1.02%
4.65
Handel nachbörslich:
460.65
Schlusskurs vom Vortag:
$456.00
Offen:
$456
24-Stunden-Volumen:
1.37M
Relative Volume:
1.21
Marktkapitalisierung:
$60.38B
Einnahmen:
$2.46B
Nettoeinkommen (Verlust:
$-319.09M
KGV:
-186.73
EPS:
-2.4669
Netto-Cashflow:
$-52.09M
1W Leistung:
+0.50%
1M Leistung:
+3.17%
6M Leistung:
+80.11%
1J Leistung:
+66.87%
1-Tages-Spanne:
$453.31
$467.42
1-Wochen-Bereich:
$442.51
$467.42
52-Wochen-Spanne:
$205.87
$484.21
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Firmenname
Alnylam Pharmaceuticals Inc
Sektor
Branche
Telefon
(617) 551-8200
Adresse
675 WEST KENDALL STREET, CAMBRIDGE, MA
Vergleichen Sie ALNY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
460.65 | 59.77B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
VRTX
Vertex Pharmaceuticals Inc
|
404.21 | 100.41B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
599.94 | 59.59B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
767.33 | 45.14B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
335.16 | 37.42B | 4.56B | -176.77M | 225.30M | -1.7177 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-04 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-08-04 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | Fortgesetzt | Raymond James | Outperform |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-03-31 | Eingeleitet | Redburn Atlantic | Buy |
| 2025-03-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-11-12 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-08-16 | Hochstufung | Goldman | Neutral → Buy |
| 2024-02-16 | Herabstufung | Goldman | Buy → Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-10-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-09-29 | Eingeleitet | Raymond James | Outperform |
| 2023-05-05 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | Eingeleitet | SMBC Nikko | Neutral |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-09-09 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-06-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-06-07 | Eingeleitet | William Blair | Outperform |
| 2022-04-25 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | Eingeleitet | Citigroup | Buy |
| 2022-02-03 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-01-03 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | Hochstufung | Goldman | Neutral → Buy |
| 2021-11-22 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-10-04 | Hochstufung | UBS | Neutral → Buy |
| 2021-08-04 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-02-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-02-12 | Bestätigt | H.C. Wainwright | Buy |
| 2021-01-25 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | Fortgesetzt | Berenberg | Hold |
| 2020-09-08 | Eingeleitet | Citigroup | Buy |
| 2020-08-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-04-24 | Fortgesetzt | Evercore ISI | Outperform |
| 2020-03-19 | Eingeleitet | Berenberg | Buy |
| 2019-12-19 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-11-20 | Eingeleitet | Oppenheimer | Outperform |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-05-23 | Fortgesetzt | Goldman | Neutral |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-03-05 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | Eingeleitet | UBS | Neutral |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-08-13 | Bestätigt | Stifel | Buy |
| 2018-08-07 | Hochstufung | Stifel | Hold → Buy |
| 2018-05-04 | Bestätigt | Stifel | Hold |
| 2018-03-28 | Eingeleitet | Evercore ISI | In-line |
Alle ansehen
Alnylam Pharmaceuticals Inc Aktie (ALNY) Neueste Nachrichten
Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra? - Yahoo Finance
Is Alnylam Pharmaceuticals Inc. (DUL) stock overpriced at current multiplesMarket Performance Recap & Weekly Return Optimization Alerts - newser.com
News impact scoring models applied to Alnylam Pharmaceuticals Inc.July 2025 Market Mood & High Accuracy Trade Signal Alerts - newser.com
Alnylam (ALNY) Begins Phase 3 Trial for Hypertension Drug Zilebe - GuruFocus
Alnylam doses first patient in phase 3 trial of zilebesiran for heart outcomes - MarketScreener
Alnylam Announces First Patient Dosed in ZENITH Global Phase 3 Cardiovascular Outcomes Trial of Zilebesiran - Business Wire
Will Alnylam Pharmaceuticals Inc. (DUL) stock announce special dividendWeekly Trading Summary & Weekly High Potential Stock Alerts - newser.com
U.S. Porphyria Treatment Market Set to Witness Massive Growth - openPR.com
Alnylam Pharmaceuticals Inc Stock Analysis and ForecastStock Buyback Announcements & Individual Stock Tracking Service - earlytimes.in
Is Alnylam Pharmaceuticals Inc. (DUL) stock attractive for dividend growth2025 Breakouts & Breakdowns & AI Forecast for Swing Trade Picks - newser.com
Alnylam’s AMVUTTRA Reduces GI Events in ATTR-CM Patients, According to New HELIOS-B Data - Yahoo Finance
$15B+ Deal Veteran Eric Olson Joins Rare Disease Leader Ultragenyx as Chief Business Officer - Stock Titan
Alnylam Joins Genomic Alliance To Boost RNAi Drug Discovery - Technology Networks
Alnylam Pharmaceuticals, Inc. (ALNY) Reports $492M Amvuttra Sales, Raises 2025 Revenue Guidance - Yahoo
Alnylam and Ionis Pharmaceuticals are the leading companies - openPR.com
Does Alnylam Pharmaceuticals Inc. show high probability of reboundRate Cut & Weekly High Potential Stock Alerts - newser.com
Gene Therapy for Rare Disease Market to Reach US$ 24.54 Bn by 2033, - openPR.com
Wealth Enhancement Advisory Services LLC Cuts Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Smart tools for monitoring Alnylam Pharmaceuticals Inc.’s price actionJuly 2025 Institutional & Verified Trade Idea Suggestions - newser.com
What indicators show strength in Alnylam Pharmaceuticals Inc.July 2025 Recap & Expert Curated Trade Ideas - newser.com
Is Alnylam Pharmaceuticals (NASDAQ:ALNY) Using Debt In A Risky Way? - Yahoo Finance
Will Alnylam Pharmaceuticals Inc. stock sustain high P E ratios2025 Buyback Activity & Fast Gain Swing Alerts - newser.com
What analysts say about Alnylam Pharmaceuticals Inc stockSell Signals and Alerts & Free High Yield Growth Strategies - earlytimes.in
Is Alnylam Pharmaceuticals Inc. stock ready for breakoutRate Hike & AI Driven Stock Reports - newser.com
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis: A Biotech Leader with Strong Buy Ratings and Strategic Collaborations - DirectorsTalk Interviews
Vutrisiran treatment reduces GI events in ATTR-CM patients by up to 49% - Investing.com Nigeria
Alnylam (ALNY): Vutrisiran Shows Promise in Reducing Gastrointes - GuruFocus
Alnylam (ALNY): Vutrisiran Shows Promise in Reducing Gastrointestinal Events - GuruFocus
Alnylam says new data from Helios-B Phase 3 study demonstrate lower rates of gastrointestinal events in ATTR-CM patients treated with Vutrisiran - MarketScreener
New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran - Business Wire
How Alnylam Pharmaceuticals' (ALNY) Entry to Genomic Data Alliance Could Shape Its Drug Pipeline Progress - simplywall.st
Sowell Financial Services LLC Takes $201,000 Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Public Employees Retirement System of Ohio - MarketBeat
$1000 Invested In Alnylam Pharmaceuticals 5 Years Ago Would Be Worth This Much Today - Benzinga
RNA-Based Therapies Industry Analysis 2025 | Growth, USA Market - openPR.com
8,994 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Purchased by ST Germain D J Co. Inc. - MarketBeat
Is Alnylam Pharmaceuticals (ALNY) an Undervalued Stock? - Insider Monkey
Does Alnylam Pharmaceuticals (ALNY) Have the Potential to Generate Strong Long-Term Growth? - Insider Monkey
TB Alternative Assets Ltd. Lowers Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Cardiac Amyloidosis Pipeline 2025: Pioneering Clinical Developments by 20+ Global Leaders – DelveInsight | Featuring Eidos Therapeutics, Intellia Therapeutics, Novo Nordisk, Alnylam Pharmaceuticals - Barchart.com
Why Alnylam Pharmaceuticals (ALNY) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Bannerman Wealth Management Group LLC Sells 565 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
IFM Investors Pty Ltd Acquires 1,508 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Assenagon Asset Management S.A. Purchases 11,281 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Exchange Traded Concepts LLC Sells 909 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Swedbank AB Has $20.97 Million Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $500.00 at Royal Bank Of Canada - MarketBeat
Pallas Capital Advisors LLC Decreases Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Finanzdaten der Alnylam Pharmaceuticals Inc-Aktie (ALNY)
Umsatz
Nettogewinn
Free Cashflow
ENV
6.70%
1.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):